Heron Therapeutics (HRTX) CEO exercises 13,797 RSUs into stock
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Heron Therapeutics Chief Executive Officer Craig A. Collard exercised restricted stock units into common shares as part of his equity compensation. He converted 13,797 restricted stock units into 13,797 shares of common stock at a stated price of $0.00 per share.
After the transaction, he directly holds 662,052 shares of common stock and 96,758 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of common stock and vests in 16 equal quarterly installments beginning one quarter after the January 19, 2024 grant date.
Positive
- None.
Negative
- None.
Insider Trade Summary
13,797 shares exercised/converted
Mixed
2 txns
Insider
Collard Craig A
Role
Chief Executive Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Restricted Stock Units | 13,797 | $0.00 | -- |
| Exercise | Common Stock | 13,797 | $0.00 | -- |
Holdings After Transaction:
Restricted Stock Units — 96,758 shares (Direct, null);
Common Stock — 662,052 shares (Direct, null)
Footnotes (1)
- Each restricted stock unit represents a contingent right to receive one share of common stock. The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (01/19/2024).
Key Figures
RSUs exercised: 13,797 units
Common shares held after: 662,052 shares
RSUs remaining: 96,758 units
+2 more
5 metrics
RSUs exercised
13,797 units
Restricted stock units converted to common stock on April 19, 2026
Common shares held after
662,052 shares
CEO direct common stock ownership after transaction
RSUs remaining
96,758 units
Restricted stock units held after the exercise
RSU conversion price
$0.00 per unit
Reported transaction and exercise price per RSU
Vesting schedule
16 quarterly installments
RSUs vest in 16 equal quarterly tranches from one quarter after 01/19/2024
Key Terms
Restricted Stock Units, contingent right, derivative security, vest
4 terms
Restricted Stock Units financial
"The restricted stock units vest in 16 equal quarterly installments"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
contingent right financial
"Each restricted stock unit represents a contingent right to receive one share"
derivative security financial
"transaction_code_description": "Exercise or conversion of derivative security"
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
vest financial
"The restricted stock units vest in 16 equal quarterly installments"
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.
FAQ
What insider transaction did Heron Therapeutics (HRTX) report for its CEO?
Heron Therapeutics reported that CEO Craig A. Collard exercised 13,797 restricted stock units into 13,797 shares of common stock. This was a compensation-related equity conversion, not an open-market stock purchase or sale, and reflects scheduled vesting of prior equity awards.
How many restricted stock units does the Heron Therapeutics (HRTX) CEO still have?
After exercising 13,797 restricted stock units, CEO Craig A. Collard holds 96,758 restricted stock units. These units continue to represent contingent rights to receive an equal number of common shares as they vest according to the disclosed quarterly vesting schedule.
What is the vesting schedule for the Heron Therapeutics (HRTX) CEO’s restricted stock units?
The CEO’s restricted stock units vest in 16 equal quarterly installments beginning one quarter after the January 19, 2024 grant date. Each vested unit converts into one share of common stock, providing a structured, time-based equity compensation program for the executive.